Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
Hereditary angioedema
Individualized treatment
Lanadelumab
Quality of life
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
09
02
2021
revised:
29
04
2021
accepted:
30
04
2021
pubmed:
24
5
2021
medline:
29
10
2021
entrez:
23
5
2021
Statut:
ppublish
Résumé
Lanadelumab has been available in Germany for the prophylactic treatment of hereditary angioedema since February 2019. To investigate real-life treatment outcome of lanadelumab and gain practical experience in adapting the therapy to individual patients. The study included 34 patients. In 24 patients with hereditary angioedema and 4 patients with angioedema due to acquired C1-inhibitor deficiency, the previous treatment was switched to lanadelumab. In 6 patients with hereditary angioedema, lanadelumab from the open-label Hereditary Angioedema Long-term Prophylaxis study was continued in regular care. During the transition, patients were monitored using the angioedema control test and the angioedema quality of life questionnaire. At the time at which patients became symptom-free, the dosage interval was increased gradually (+3 days). On average, the angioedema control test values improved from 7.5 (poorly controlled disease) to 14.9 (well-controlled disease), and all patients showed adequate disease control. All treated patients, except 1 outlier, scored angioedema quality of life questionnaire values representing only a slight reduction in quality of life (mean, 14 points). At the time point of data collection, 9 patients used an average fixed injection interval of 30 days. Twenty-two patients were symptom-free from the beginning of the treatment phase and intended to extend their injection interval from 30 to 32.5 days (median). We recommended reducing the initial dosing interval from 24 to 21 days (median) to 3 patients because of intermediately occurring symptoms. Gradual extension of injection intervals of lanadelumab presented in this study can minimize the burden of therapy without losing efficacy.
Sections du résumé
BACKGROUND
Lanadelumab has been available in Germany for the prophylactic treatment of hereditary angioedema since February 2019.
OBJECTIVE
To investigate real-life treatment outcome of lanadelumab and gain practical experience in adapting the therapy to individual patients.
METHODS
The study included 34 patients. In 24 patients with hereditary angioedema and 4 patients with angioedema due to acquired C1-inhibitor deficiency, the previous treatment was switched to lanadelumab. In 6 patients with hereditary angioedema, lanadelumab from the open-label Hereditary Angioedema Long-term Prophylaxis study was continued in regular care. During the transition, patients were monitored using the angioedema control test and the angioedema quality of life questionnaire. At the time at which patients became symptom-free, the dosage interval was increased gradually (+3 days).
RESULTS
On average, the angioedema control test values improved from 7.5 (poorly controlled disease) to 14.9 (well-controlled disease), and all patients showed adequate disease control. All treated patients, except 1 outlier, scored angioedema quality of life questionnaire values representing only a slight reduction in quality of life (mean, 14 points). At the time point of data collection, 9 patients used an average fixed injection interval of 30 days. Twenty-two patients were symptom-free from the beginning of the treatment phase and intended to extend their injection interval from 30 to 32.5 days (median). We recommended reducing the initial dosing interval from 24 to 21 days (median) to 3 patients because of intermediately occurring symptoms.
CONCLUSIONS
Gradual extension of injection intervals of lanadelumab presented in this study can minimize the burden of therapy without losing efficacy.
Identifiants
pubmed: 34023564
pii: S2213-2198(21)00581-X
doi: 10.1016/j.jaip.2021.04.072
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Complement C1 Inhibitor Protein
0
lanadelumab
2372V1TKXK
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3744-3751Informations de copyright
Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.